Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2020.1713754
Abstract: ABSTRACT Introduction: Certolizumab pegol (CZP) is an Fc-free PEGylated TNF-α inhibitor approved for the treatment of psoriatic arthritis (PsA) and plaque psoriasis in many countries. It demonstrated favorable results in PsA in terms of improvement… read more here.
Keywords: certolizumab pegol; plaque psoriasis; treatment; arthritis ... See more keywords
Ixekizumab in the treatment of psoriatic arthritis.
Sign Up to like & getrecommendations! Published in 2020 at "Immunotherapy"
DOI: 10.2217/imt-2020-0225
Abstract: Psoriatic arthritis (PsA) is a heterogeneous chronic rheumatic disorder with numerous phenotypic facets. A better in deep understanding of the pathophysiologic mechanisms leading to psoriasis and PsA has contributed to the introduction of novel therapeutic… read more here.
Keywords: psoriatic arthritis; psa; ixekizumab treatment; treatment psoriatic ... See more keywords